MedPath

A clinical trial to compare the efficacy of Yashtimadhu Ghrita anal infiltration and Diltiazem topical application in the management of chronic anal fissure

Phase 2
Conditions
Health Condition 1: K90-K95- Other diseases of the digestive systemHealth Condition 2: K928- Other specified diseases of the digestive system
Registration Number
CTRI/2023/05/052302
Lead Sponsor
CCRAS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients of either sex aged 18-60 years.

2. Patients with chronic anal fissure greater than 6 weeks of duration.

3. Willing to provide written informed consent.

Exclusion Criteria

1. Patients with co-morbidities such as fistula in ano, haemorrhoids, perianal abscess, clinically evident fecal incontinence, anal stenosis/fibrosis

2. Patients with inflammatory bowel disease, tuberculosis, diabetes mellitus, anemia, malnourishment caused by systemic diseases, malignancy, HIV, STDs, hepatitis B

3. Patients with uncontrolled hypertension, clinically significant renal disease, hepatic disease, cardiovascular disease, psychiatric disease

4. Fissure associated with abscess, drug-induced fissure or fissure resulting from external trauma

5. Fissure located at lateral locations and multiple fissures

6. Patients on medications hampering wound healing (corticosteroids, NSAIDs, anti-convulsants, anticoagulants, immunosuppressive agents etc.)

7. Patients using oral calcium channel blockers

8. Patients with frequent h/o headache

9. Active substance abuse

10. Known hypersensitivity to either of the trial interventions

11. Pregnant and lactating women

12.Patients who have been using either of the trial interventions prior to 30 days of randomization

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of participants having complete healing of the chronic anal fissureTimepoint: 30 days
Secondary Outcome Measures
NameTimeMethod
Incidence of adverse events during the study periodTimepoint: 30 days;Pain during defecationTimepoint: day 8, 15, 22, 30;Proportion of participants having complete healing of the chronic anal fissureTimepoint: after one week <br/ ><br>;Recurrence of anal fissure after complete healingTimepoint: day 60, day 90 and day 180;Time to cessation of bleedingTimepoint: day 8, 15, 22 & 30
© Copyright 2025. All Rights Reserved by MedPath